Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Buys $300,300.00 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi purchased 130,000 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the acquisition, the director now owns 130,000 shares of the company’s stock, valued at $300,300. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.38 on Friday. The firm’s 50 day moving average price is $2.29 and its two-hundred day moving average price is $2.31. Ventyx Biosciences, Inc. has a 52-week low of $1.67 and a 52-week high of $11.48. The stock has a market cap of $168.29 million, a PE ratio of -1.01 and a beta of 0.48.

Wall Street Analyst Weigh In

VTYX has been the subject of several research reports. HC Wainwright reissued a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reiterated an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C increased its holdings in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares during the last quarter. Sio Capital Management LLC grew its position in shares of Ventyx Biosciences by 153.2% during the 3rd quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after buying an additional 1,193,024 shares during the period. Vestal Point Capital LP increased its stake in shares of Ventyx Biosciences by 31.2% in the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at approximately $608,000. Finally, XTX Topco Ltd bought a new position in Ventyx Biosciences during the 3rd quarter worth approximately $246,000. 97.88% of the stock is currently owned by institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.